| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| GMEDGlobus Medical, Inc. | 10.46B | 93.89 | 125.19 | 60.62% | 15.3% | 9.63% | 3.87% | 0.13 |
| TNONTenon Medical, Inc. | 10.6M | 0.95 | -0.08 | 11.92% | -396.26% | -267.01% | 0.07 | |
| BBLGBone Biologics Corporation | 3M | 1.67 | -0.35 | -65.59% | ||||
| OFIXOrthofix Medical Inc. | 570.24M | 14.40 | -4.36 | 7.08% | -14.56% | -26.92% | 0.36 | |
| XTNTXtant Medical Holdings, Inc. | 91M | 0.65 | -5.42 | 28.44% | 1.32% | 3.48% | 0.82 | |
| ATECAlphatec Holdings, Inc. | 2.59B | 17.46 | -15.45 | 26.81% | -21.29% | -13.47% | 64.65 | |
| SIBNSI-BONE, Inc. | 762.82M | 17.58 | -23.44 | 20.37% | -11.24% | -12.64% | 0.22 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 53.64K | 43.82K | 160K | 691K | 2.93M | 3.28M |
| Revenue Growth % | - | -0.18% | 2.65% | 3.32% | 3.24% | 0.12% |
| Cost of Goods Sold | 18.26K | 18.26K | 55K | 1.33M | 1.69M | 1.57M |
| COGS % of Revenue | 0.34% | 0.42% | 0.34% | 1.93% | 0.58% | 0.48% |
| Gross Profit | 35.38K | 25.56K | 105K | -641K | 1.24M | 1.71M |
| Gross Margin % | 0.66% | 0.58% | 0.66% | -0.93% | 0.42% | 0.52% |
| Gross Profit Growth % | - | -0.28% | 3.11% | -7.1% | 2.94% | 0.38% |
| Operating Expenses | 568.83K | 561.85K | 6.57M | 18.08M | 16.97M | 15.48M |
| OpEx % of Revenue | 10.6% | 12.82% | 41.04% | 26.17% | 5.8% | 4.72% |
| Selling, General & Admin | 197.28K | 340.97K | 4.85M | 15.26M | 13.8M | 12.87M |
| SG&A % of Revenue | 3.68% | 7.78% | 30.3% | 22.08% | 4.71% | 3.93% |
| Research & Development | 371.55K | 220.88K | 1.72M | 2.83M | 3.16M | 2.6M |
| R&D % of Revenue | 6.93% | 5.04% | 10.74% | 4.09% | 1.08% | 0.79% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -533.44K | -536.29K | -6.46M | -18.73M | -15.73M | -13.77M |
| Operating Margin % | -9.94% | -12.24% | -40.38% | -27.1% | -5.37% | -4.2% |
| Operating Income Growth % | - | -0.01% | -11.05% | -1.9% | 0.16% | 0.12% |
| EBITDA | 2 | -537.52K | -6.35M | -18.44M | -15.3M | -13.11M |
| EBITDA Margin % | 0% | -12.27% | -39.67% | -26.68% | -5.23% | -4% |
| EBITDA Growth % | - | -268760.5% | -10.81% | -1.9% | 0.17% | 0.14% |
| D&A (Non-Cash Add-back) | 533.44K | 0 | 114K | 289K | 426K | 655K |
| EBIT | -533.47K | -537.52K | -6.46M | -18.56M | -15.56M | -13.64M |
| Net Interest Income | 0 | -167.85K | -621K | -354K | -21K | -34K |
| Interest Income | 52.36K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 52.36K | 167.85K | 621K | 354K | 21K | 34K |
| Other Income/Expense | -52.39K | -169.08K | -620K | -192K | 146K | 93K |
| Pretax Income | -585.83K | -705.37K | -7.08M | -18.92M | -15.58M | -13.67M |
| Pretax Margin % | -10.92% | -16.1% | -44.26% | -27.38% | -5.32% | -4.17% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.87% | 0.83% | 1% | 1% | 1% | 1% |
| Net Income | -509.58K | -585.18K | -7.05M | -18.92M | -15.58M | -13.67M |
| Net Margin % | -9.5% | -13.35% | -44.05% | -27.38% | -5.32% | -4.17% |
| Net Income Growth % | - | -0.15% | -11.04% | -1.68% | 0.18% | 0.12% |
| Net Income (Continuing) | -585.83K | -705.37K | -7.08M | -18.92M | -15.58M | -13.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 994.68K | 1.71M | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -49.12 | -56.40 | -624.38 | -187.30 | -68.64 | -11.26 |
| EPS Growth % | - | -0.15% | -10.07% | 0.7% | 0.63% | 0.84% |
| EPS (Basic) | -49.12 | -56.40 | -624.38 | -187.30 | -68.64 | -11.26 |
| Diluted Shares Outstanding | 10.38K | 10.38K | 11.29K | 101K | 227K | 1.21M |
| Basic Shares Outstanding | 10.38K | 10.38K | 11.29K | 101K | 227K | 1.21M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 268.45K | 303.4K | 7.67M | 9.35M | 3.89M | 8.21M |
| Cash & Short-Term Investments | 151.97K | 245.63K | 7.32M | 8.57M | 2.43M | 6.54M |
| Cash Only | 151.97K | 245.63K | 2.92M | 2.13M | 2.43M | 6.54M |
| Short-Term Investments | 0 | 0 | 4.4M | 6.44M | 0 | 0 |
| Accounts Receivable | 53.77K | 14.47K | 76K | 241K | 526K | 863K |
| Days Sales Outstanding | 365.87 | 120.56 | 173.38 | 127.3 | 65.57 | 96.12 |
| Inventory | 61.55K | 43.29K | 188K | 415K | 554K | 606K |
| Days Inventory Outstanding | 1.23K | 865.43 | 1.25K | 113.72 | 119.86 | 141.25 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 206K |
| Total Non-Current Assets | 0 | 87.5K | 1.6M | 1.74M | 2.46M | 1.63M |
| Property, Plant & Equipment | 0 | 0 | 1.19M | 1.67M | 1.61M | 1.15M |
| Fixed Asset Turnover | - | - | 0.14x | 0.41x | 1.82x | 2.85x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 87.5K | 415K | 76K | 849K | 482K |
| Total Assets | 268.45K | 390.9K | 9.27M | 11.09M | 6.34M | 9.84M |
| Asset Turnover | 0.20x | 0.11x | 0.02x | 0.06x | 0.46x | 0.33x |
| Asset Growth % | - | 0.46% | 22.72% | 0.2% | -0.43% | 0.55% |
| Total Current Liabilities | 1.69M | 1.49M | 15.27M | 2.53M | 3.14M | 1.87M |
| Accounts Payable | 447.52K | 589.19K | 478K | 550K | 433K | 369K |
| Days Payables Outstanding | 8.95K | 11.78K | 3.17K | 150.71 | 93.68 | 86.01 |
| Short-Term Debt | 734.41K | 241.4K | 13.51M | 228K | 1.17M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 28.69K | 80.75K | 846K | 1.3M | 474K | 0 |
| Current Ratio | 0.16x | 0.20x | 0.50x | 3.69x | 1.24x | 4.39x |
| Quick Ratio | 0.12x | 0.17x | 0.49x | 3.53x | 1.06x | 4.07x |
| Cash Conversion Cycle | -7.35K | -10.79K | -1.75K | 90.31 | 91.75 | 151.36 |
| Total Non-Current Liabilities | 193.39K | 333.58K | 14.55M | 2.31M | 2.43M | 2M |
| Long-Term Debt | 193.39K | 333.58K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 911K | 683K | 428K | 141K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 2M | 0 |
| Other Non-Current Liabilities | 0 | 0 | 13.64M | 1.62M | 2M | 1.86M |
| Total Liabilities | 1.88M | 1.83M | 29.82M | 4.84M | 5.57M | 3.87M |
| Total Debt | 927.8K | 574.98K | 14.62M | 911K | 1.86M | 428K |
| Net Debt | 775.84K | 329.34K | 11.7M | -1.22M | -571K | -6.11M |
| Debt / Equity | - | - | - | 0.15x | 2.39x | 0.07x |
| Debt / EBITDA | 463902.00x | - | - | - | - | - |
| Net Debt / EBITDA | 387918.00x | - | - | - | - | - |
| Interest Coverage | -10.19x | -3.20x | -10.40x | -52.90x | -748.90x | -404.88x |
| Total Equity | -1.61M | -1.44M | -20.55M | 6.25M | 778K | 5.97M |
| Equity Growth % | - | 0.11% | -13.3% | 1.3% | -0.88% | 6.67% |
| Book Value per Share | -155.57 | -138.50 | -1820.69 | 61.90 | 3.43 | 4.92 |
| Total Shareholders' Equity | -2.61M | -3.14M | -20.55M | 6.25M | 778K | 5.97M |
| Common Stock | 1.66K | 1.66K | 1K | 11K | 3K | 3K |
| Retained Earnings | -3.9M | -4.49M | -20.57M | -39.49M | -55.07M | -68.75M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -32.41K | -56.57K | -91K | -100K | -46K | 0 |
| Minority Interest | 994.68K | 1.71M | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -235.2K | -167.36K | -4.29M | -12.03M | -12.18M | -9.88M |
| Operating CF Margin % | -4.38% | -3.82% | -26.82% | -17.4% | -4.16% | -3.01% |
| Operating CF Growth % | - | 0.29% | -24.64% | -1.8% | -0.01% | 0.19% |
| Net Income | -509.58K | -705.37K | -7.08M | -18.92M | -15.58M | -13.67M |
| Depreciation & Amortization | 0 | 0 | 114K | 289K | 426K | 655K |
| Stock-Based Compensation | 30.57K | 16.65K | 377K | 2.9M | 4.14M | 3.85M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -24.76K | 167.78K | 1.85M | 1.98M | 0 | 41K |
| Working Capital Changes | 268.56K | 353.57K | 452K | 1.72M | -1.17M | -746K |
| Change in Receivables | -53.39K | 39.36K | -61K | -152K | -290K | -386K |
| Change in Inventory | -61.55K | 18.26K | -145K | -227K | -139K | -52K |
| Change in Payables | 271.34K | 141.28K | 444K | 72K | -117K | -64K |
| Cash from Investing | 64.49K | 0 | -4.5M | -2.88M | 6.14M | -186K |
| Capital Expenditures | 0 | 0 | -102K | -847K | -361K | -186K |
| CapEx % of Revenue | - | - | 0.64% | 1.23% | 0.12% | 0.06% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 64.49K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 321.31K | 254.8K | 11.47M | 14.11M | 6.3M | 14.13M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | -51.82K | -358K | -25K | -251K | 4.36M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -235.2K | -167.36K | -4.39M | -12.87M | -12.54M | -10.06M |
| FCF Margin % | -4.38% | -3.82% | -27.46% | -18.63% | -4.28% | -3.07% |
| FCF Growth % | - | 0.29% | -25.25% | -1.93% | 0.03% | 0.2% |
| FCF per Share | -22.67 | -16.13 | -389.26 | -127.45 | -55.26 | -8.29 |
| FCF Conversion (FCF/Net Income) | 0.46x | 0.29x | 0.61x | 0.64x | 0.78x | 0.72x |
| Interest Paid | 0 | 66 | 1K | 0 | 0 | 0 |
| Taxes Paid | 0 | 2.03K | 1K | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -302.58% | -443.27% | -405.19% |
| Return on Invested Capital (ROIC) | - | - | - | - | -450.11% | -29083.1% |
| Gross Margin | 65.96% | 58.34% | 65.63% | -92.76% | 42.38% | 52.21% |
| Net Margin | -950% | -1335.41% | -4405% | -2737.63% | -532.14% | -417.24% |
| Debt / Equity | - | - | - | 0.15x | 2.39x | 0.07x |
| Interest Coverage | -10.19x | -3.20x | -10.40x | -52.90x | -748.90x | -404.88x |
| FCF Conversion | 0.46x | 0.29x | 0.61x | 0.64x | 0.78x | 0.72x |
| Revenue Growth | - | -18.31% | 265.13% | 331.88% | 323.73% | 11.92% |
| 2024 | |
|---|---|
| Other Operating | 3.28M |
| Other Operating Growth | - |
Tenon Medical, Inc. (TNON) reported $3.2M in revenue for fiscal year 2024. This represents a 5927% increase from $0.1M in 2019.
Tenon Medical, Inc. (TNON) grew revenue by 11.9% over the past year. This is steady growth.
Tenon Medical, Inc. (TNON) reported a net loss of $12.8M for fiscal year 2024.
Tenon Medical, Inc. (TNON) has a return on equity (ROE) of -405.2%. Negative ROE indicates the company is unprofitable.
Tenon Medical, Inc. (TNON) had negative free cash flow of $11.3M in fiscal year 2024, likely due to heavy capital investments.